تیپیکو

#Tipico The 12 -month Miandore Information and Financial Statement reports ended in fiscal year 1404/02/31 (unattended) Net 12 months: 5017.5 billion tomans increased by 45 % compared to the same year. 🔥 Kord's net profit was broken. The accumulated safety of 5167.1 billion tomans increased by 28 % compared to last year. Seasonal Profit: 4561 Rials P / e: 6.15 P / O group: 10.26 Stock number: 11 billion Market value: 30,844 billion USD Support your shares by submitting this report on the channel and the stock exchange groups 🇮🇷@dndir

#Tipico #Future Futures End of Fiscal Year ending 1404/02/31 (Uncategorized) Company 🟠 The supply pharmaceutical investment company has identified 4,561 riyals per share for the 12 -month period ended at 31/404, which is 45 % compared to the same period last year.

#Tipico The 12 -month Miandore Information and Financial Statement reports ended in fiscal year 1404/02/31 (unattended) Net 12 months: 5017.5 billion tomans increased by 45 % compared to the same year. 🔥 Kord's net profit was broken. The accumulated safety of 5167.1 billion tomans increased by 28 % compared to last year. Seasonal Profit: 4561 Rials P / e: 6.15 P / O group: 10.26 Stock number: 11 billion Market value: 30,844 billion USD Support your shares by submitting this report on the channel and the stock exchange groups 🇮🇷@dndir

#Tipico Reported the spring season. Before reporting EPS = 3645 Next the report EPS = 4561 I had no previous forecast. PE = 6.15 Eps adjustment rate = 0.25 The report was great.

✅ Treaty growth of Tipico's profit over one year According to Stock Exchange 24, the supply pharmaceutical investment company, which operates with the Tipico symbol on the Tehran Stock Exchange, released its unattended financial statements of the twelve months ending May 1403. 🔗 Read more ... @Bourse24ir

#Tipico #Future Futures End of Fiscal Year ending 1404/02/31 (Uncategorized) Company ▪️ The Pharmaceutical Investment Company has identified 4,561 riyals per share of 4,561 riyals in the 12 -month period ending 31/404, which is 45 % compared to the same period last year. ▪️ Tipico has identified 50,174,994 million rials with a record of 11,000,000 million Rials over 12 months of performance ending to 140/02/31. 1404-04-28 20:22:06 (1373746) ایرین ایرین @codal360_ir

#Tipico 💹 @tse_plus 📅 1404/4/25 ⌚ 10:03:26 🔖 28,160 #Purchase 1 real code in the case of 0.54 boards  Value 4,359,055,360 Rials

#Assembly #Depars 📌 According to the report of the conscious voice; The annual general meeting of Pars Daru Company was held with the participation of the shareholders. The most important points in this session are as follows: In year 2, Pars Daru product basket had a major flaw; The life of its products was the same as the domestic product. In year 6, with the completion of the raw materials, the basket improved and became more complete. In the past, the company had a 6 -month -old aspirin depot, which was difficult to sell. Fortunately, this warehouse has now declined to two months. It will be prevented from reducing the company's discounts this year, thereby improving the net profit margin. The company used by the company is supplied at a rate of 4 USD, but part of it is purchased at preferential rates (close to the free market). The receipt of the claims within the group is 2 days and outside the group 2 days. Tipico Company has announced that Pars Drug sales policy is based on the interests of the company. Customer needs are reviewed and met by re -reading sessions. In year 4, the company was able to fully supply the raw materials needed for drug production. There was no important product in the market that Pars Drug did not produce. این The destruction of the distributors has been due to the lack of liquidity in the company. At the end of the assembly, 2 % of the company's profits, equivalent to 2 Rials per share, were divided among shareholders.

#Tipico 💹 @tse_plus 📅 1404/4/23 ⌚ 11:38:07 🔖 28,150 #Buy 2 real code in the case of 1.92 panels  Value 7,521,088,850 Rials Per capita purchase of each code 3,673,800,200 Rials

#Spars Assembly Pars Daru Company was established in 2007 by Bayer Pharama Iran Company by Bayer Germany as the first branch of a multinational and pharmaceutical company in Iran and was put into operation in year 6. The company's registration capital at the time of its establishment was 3 million Rials The company entered the capital market in year 6 The last increase in the company's capital from 5 million shares to 5 million shares was 2 % of the stock Pars Daru Company is ranked 1 among the stock market for the sale. One shareholder asked about reducing the company's sales trend The CEO of the company said: According to Tipiko, the company's sales policy is based on the company's interests. We meet their requests according to their needs, according to their needs In year 4, we were able to supply the raw materials needed for drug production, in the fiscal year, there were no important and important products in the market that Pars Drug did not produce. The discounts we give to distributors have been due to the lack of liquidity in the company. Another shareholder asked about the exchange rate needed to buy raw materials The company's CEO explained: The products of the company are currently in the currency of 4,000 tomans, but some products are supplied at preferential exchange rate @Bourse24ir